RAFT® 14 出展・発表のお知らせ

味の素バイオ・ファーマ サービスは、2022年11月6日(日)~9日(水)開催の第14回 RAFT®に出展いたします。
またScientific sessionにおいてCORYNEX®についての発表を行います。皆様のご来場をお待ちしております。

展示会名 RAFT® 14
会期 2022年11月6日(日)〜9日(水)
場所(会場) Caribe Royale Orlando, Orlando, FL
出展 Tabletop 7
[発表]Alternative systems to animal cell culture
演題・発表者 “CORYNEX®: Suitable protein expression system for antibody mimetics using Corynebacterium glutamicum
Hayato Nagano, Ajinomoto Co., Inc.
要旨 Corynebacterium glutamicum discovered as a natural producer of glutamate is a gram-positive, non-sporulating, and non-pathogenic bacterium. For several decades, this strain has been heavily used in industrial production of amino acids, which are used in human food additive, animal feed additive, and pharmaceutical products. We have developed a unique recombinant protein secretion system by using C. glutamicum and protein expression service CORYNEX®.

This system has some advantages compared with other protein expression systems. First, C. glutamicum hardly secrete host cell proteins of itself into the culture supernatant. Therefore, the target protein can be secreted with high purity. Second advantage is about correct folding of the secreted protein. A protein which has complex structure such as including disulfide bonds, homo-dimer, and hetero-dimer can be secreted as active form. Third advantage is endotoxin-free. C. glutamicum is a gram-positive bacterium, which does not produce endotoxin natively. So, it is not needed to care about endotoxin clearance during manufacturing process.

To expand the versatility of this system, we developed the CspB-fusion method to increase the secretion titer, and identified the Tat-pathway, which is a novel protein secretion pathway that differs from general protein-secretion pathway well known as Sec-pathway. Furthermore, we have developed efficient breeding technologies, such as signal peptide library and host strain library, to improve the productivity.

Now we are applying this system to produce biopharmaceuticals. So far, several proteins produced by this system have already been tested in clinical trials in US and EU. Recently, there are focused on antibody mimetic proteins as well as conventional major antibody therapeutics in the biopharma field, so we have tried the strain development to produce these proteins. As a result, various kinds of proteins could be successfully secreted, so it was demonstrated that CORYNEX® is very suitable system to produce antibody mimetics and fragment antibodies.

In this presentation, we introduce the detail and case study of CORYNEX® technology, and the perspective of the Ajinomoto’s biopharma services including contract development and manufacturing organization (CDMO) business.

日時・場所 2022年11月8日(水) 15:10
Caribe Royale Orlando – Grand Sierra E